Hematopoietic Stem Cells (HSCs)

$15M Upstate Cord Blood Bank Opens in Syracuse, NY

February 9, 2017 By Cade Hildreth, Founder & President Leave a Comment

On February 9, 2017, Upstate Cord Blood Bank in Syracuse, NY, opened its doors. The planning and construction was a lengthy process and cost $15 million.

The project origins go back to 2006 when the center was first proposed. Unfortunately, state funding for the project was delayed in 2008 due to economic conditions, and the build out of the cord blood bank was further delayed when design changes were implemented during construction. Senator John DeFrancisco had a pivotal role in securing state funding for the cord blood bank. [Read more…]

GenCure, StemBioSys Forge Stem Cell Product Manufacturing Agreement

January 30, 2017 By Cade Hildreth, Founder & President Leave a Comment

GenCure will be exclusive producer for StemBioSys-developed regenerative medicine products

January 30, 2017, SAN ANTONIO – GenCure, a subsidiary of San Antonio-based biotech BioBridge Global, has entered a development and manufacturing agreement with stem cell technology developer StemBioSys Inc. of San Antonio. [Read more…]

WideCells’ CellPlan Insurance is Live – 1st Sales Made to Biovault’s Base of Cord Blood Banks

January 8, 2017 By Cade Hildreth, Founder & President Leave a Comment

World first stem cell insurance plan, CellPlan, secures maiden sales agreement signaling commencement of commercial roll out.

CellPlan Limited (‘CellPlan’), which has developed the world’s first stem cell healthcare insurance plan and medical concierge service, has cemented its agreement with Biovault Technical Ltd (‘Biovault’), the UK’s largest private human tissue storage facility via a definitive agreement. CellPlan is part of London-listedWideCells Group plc, the healthcare services company focused on providing end-to-end stem cell services. [Read more…]

30 Key Patents about Cord Blood (UPSTO)

December 13, 2016 By Cade Hildreth, Founder & President Leave a Comment

A crucial benchmark to track for the cord blood market is the number and type of cord blood related patents that have been issued.

The United States Patent and Trademark Office (USPTO) has a patent analysis tool that offers a “Full Text and Image Database Search.” The database includes information about all American patents, from the first patent issued in 1790 to the most recent issue week.¹ The text of patents issued from January 1976 to the present is fully searchable, including bibliographic data, such as the inventor’s name, the patent’s title, and the assignee’s name; the abstract; the full description of the invention; and the claims.² [Read more…]

Global Cooperation – MD Anderson and NIH to Fund Clinical Trial Combining Mesoblast Technologies

December 8, 2016 By Cade Hildreth, Founder & President Leave a Comment

MD Anderson Cancer Center and National Institutes of Health to Fund Trial Combining 2 Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients

New York, USA; and Melbourne, Australia; December 6, 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that MD Anderson Cancer Center (MDACC) in Texas and the United States National Institutes of Health (NIH) will fund a clinical trial combining Mesoblast’s two synergistic proprietary technologies, Mesenchymal Precursor Cell (MPC)-based expansion and ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplantation in cancer patients. The trial will provide clinical data on whether the combination of these two technologies synergistically facilitates more rapid cord blood HSC engraftment for bone marrow transplant patients than can be achieved by either technology alone.

The number of allogeneic bone marrow transplants performed globally each year could be substantially increased beyond the current 30,000, for cancer and non-cancer indications, if safe and effective alternative sources of allogeneic HSCs are available, such as cord blood, for patients who cannot find a matched donor. Unfortunately, cord blood transplants are associated with prolonged engraftment times due to insufficient numbers and inadequate homing capacity of cord blood HSCs, adversely impacting their clinical outcomes. [Read more…]